Prometheus Laboratories

NCT00113503

Imuran Dosing in Crohn's Disease Study

NCT00338377

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

NCT00676832

Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis

NCT01416831

Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

NCT01366092

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

NCT01896271

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

NCT02306954

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

NCT02340676

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD

NCT02793778

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

NCT02796352

A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study

NCT02964078

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

NCT03476174

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma